Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
Inc (NASDAQ:ESPR) struck a deal with Alkem Laboratories regarding the sale of rival generic drugs. Specifically, Esperion got Alkem to agree that it would not sell generic versions of Esperion's drugs NEXLETOL and NEXLIZET in the US market before April 19, 2040. This deal with Alkem is part of Esperion's ongoing campaign to delay generic competition for NEXLETOL and NEXLIZET. On January 11, Esperion announced that it had reached a deal restricting Dr. Reddy's Laboratories and at least three other companies from introducing generic versions of its drugs before April 2040. Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements These generic drug agreements come at a time when Esperion has outlined its Vision 2040 plan. In this plan, Esperion is focused on becoming a leader in cardiometabolic disease therapies. Toward this end, the company aims to have at least five products on the market, build a robust pipeline that addresses various unmet medical
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth [Yahoo! Finance]Yahoo! Finance
- HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript [Seeking Alpha]Seeking Alpha
- Esperion Therapeutics (ESPR) had its price target raised by Needham & Company LLC from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)Business Wire
ESPR
Earnings
- 11/6/25 - Miss
ESPR
Sec Filings
- 3/3/26 - Form 8-K
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- ESPR's page on the SEC website